Volume | 900,111 |
|
|||||
News | - | ||||||
Day High | 1.595 | Low High |
|||||
Day Low | 1.51 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.58 | 1.51 | 1.595 | 1.53 | 1.52 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,832 | 900,111 | $ 1.55 | $ 1,393,393 | - | 0.5901 - 2.31 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:20:20 | formt | 100 | $ 1.54 | USD |
Atossa Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
190.46M | 125.30M | - | 0 | -30.09M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atossa Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.43 | 1.595 | 1.32 | 1.46 | 1,321,106 | 0.11 | 7.69% |
1 Month | 1.84 | 2.31 | 1.24 | 1.75 | 2,737,853 | -0.30 | -16.30% |
3 Months | 0.835 | 2.31 | 0.8279 | 1.59 | 1,772,401 | 0.705 | 84.43% |
6 Months | 0.6557 | 2.31 | 0.62 | 1.44 | 1,026,633 | 0.8843 | 134.86% |
1 Year | 0.6202 | 2.31 | 0.5901 | 1.26 | 852,263 | 0.9198 | 148.31% |
3 Years | 1.77 | 9.80 | 0.50 | 3.76 | 3,324,485 | -0.23 | -12.99% |
5 Years | 3.08 | 9.80 | 0.50 | 3.18 | 3,495,863 | -1.54 | -50.00% |
Atossa Therapeutics Description
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |